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Abstract 
Introduction: Pneumococcal pneumonia (PP) has a high burden of morbimortality in children. Use of pneumococcal conjugate vaccines 
(PCVs) is an effective preventive measure. After PCV 7-valent (PCV7) withdrawal, PCV 10-valent (PCV10) and PCV 13-valent (PCV13) 
are the alternatives in Peru. This study aimed to evaluate cost effectiveness of these vaccines in preventing PP in Peruvian children <5 years-
old.  
Methodology: A cost-effectiveness analysis was developed in three phases: a systematic evidence search for calculating effectiveness; a cost 
analysis for vaccine strategies and outcome management; and an economic model based on decision tree analysis, including deterministic and 
probabilistic sensitivity analysis using acceptability curves, tornado diagram, and Monte Carlo simulation. A hypothetic 100 vaccinated 
children/vaccine cohort was built. An incremental cost-effectiveness ratio (ICER) was calculated.  
Results: The isolation probability for all serotypes in each vaccine was estimated: 38% for PCV7, 41% PCV10, and 17% PCV13. Avoided 
hospitalization was found to be the best effectiveness model measure. Estimated costs for PCV7, PCV10, and PCV13 cohorts were 
USD13,761, 11,895, and 12,499, respectively. Costs per avoided hospitalization were USD718 for PCV7, USD333 for PCV10, andUSD 162 
for PCV13. At ICER, PCV7 was dominated by the other PCVs. Eliminating PCV7, PCV13 was more cost effective than PCV10 (confirmed 
in sensitivity analysis).  
Conclusions: PCV10 and PCV13 are more cost effective than PCV7 in prevention of pneumonia in children <5 years-old in Peru. PCV13 
prevents more hospitalizations and is more cost-effective than PCV10. These results should be considered when making decisions about the 
Peruvian National Inmunizations Schedule. 
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Infections due to Streptococcus pneumoniae are 
major causes of morbidity, hospitalization, and 
mortality in children. S. pneumoniae causes invasive 
pneumococcal diseases (IPDs) (e.g., meningitis and 
bacteremia) and non-invasive pneumococcal diseases 
(e.g., community-acquired pneumonia [CAP] and 
acute otitis media [AOM]) [1-4]. Prevention is 
complex because there are 94 serotypes. However, 
approximately 80% of all IPDs are caused by 20 
serotypes [1,5].  
Introduction of pneumococcal conjugate vaccines 
(PCVs) occurred in the United States in 2000, and 
later in Europe in 2001, when the Food and Drug 
Administration (FDA) and the European Medicines 
Agency (EMA), respectively, authorized the 7-valent 
vaccine (PCV7). This vaccine included serotypes 4, 
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6B, 9V, 14, 18C, 19F, and 23F [6,7]. In other regions 
of the world, such as Southeast Asia and Latin 
America, and the Caribbean, PCVs have been 
approved for use since 2005 and 2007, respectively 
[8,9]. Peru included PCVs in 2009 [10]. PCV7 has 
been demonstrated to be effective in preventing CAP 
and IPDs in children [11-14]. However, years after its 
introduction, there has been a change in S. pneumoniae 
serotype distribution [9,14-16].  
In 2009 in Europe and in 2010 in the United 
States, the 10-valent (PCV10) vaccine, which added 
serotypes 1, 5 and 7F to PCV7 serotypes, and the 13-
valent (PCV13) vaccine, which further added 
serotypes 3, 6A and 19A to PCV10 serotypes, were 
introduced to cover a broader range of serotypes [17-
21]. In order to support the adoption of PCVs for 
vaccination schedules of immunization programs, 
cost-effectiveness studies have been performed in 
various countries [22-29]. However, in Latin America, 
few previous studies have evaluated the 
pharmacoeconomic and economic impact of PCV10 
and PCV13 [26,30-35]; none of these studies were 
conducted in Peru by a non-pharmaceutically funded 
institution.  
In 2011, the manufacturer of PCV7 stopped its 
worldwide distribution. Therefore, PCV7 had to be 
replaced by PCV10 or PCV13. In this context, 
economic evaluations (EEs) are necessary tools for 
choosing to include either PCV10 or PCV13 in the 
Peruvian National Immunizations Schedule (PNIS). 
EEs are instruments that measure costs and health 
effects and describe the comparative efficiency of 
services and health interventions (e.g., drugs, 
technologies, procedures, public health interventions). 
Among them, the cost-effectiveness analysis (CEA) is 
the most important [36,37-67].  
 
Objective 
We estimated the cost-effectiveness of PCV10 and 
PCV13 in the prevention of pneumococcal pneumonia 
(PP) in children under five years of age in Peru, 
considering current vaccination with PCV7 as the 
baseline strategy.  
 
Methodology 
Target population, setting, location, and study 
perspective  
A cost-effectiveness analysis from the perspective 
of the government was conducted. The population 
included a hypothetical cohort of children under five 
years of age in Peru, and the cost estimation was based 
on 2011 information from the Peruvian Ministry of 
Health (MINSA). The international recommendations 
for performing health economic evaluations were used 
[38]. Peru ranked 82 in the Human Development 
Index (0.737) in 2013 (reported in 2014); it is a high 
human development country with a life expectancy of 
74.8 years and a gross national income (GNI) per 
capita of USD 11,280 [68]. 
This study included three phases. The first phase 
involved a systematic search of literature for 
estimating PCV effectiveness. The second phase 
included the development of a costing frame related to 
the intervention and treatment. Finally, the third phase 
was the development of a pharmacoeconomic model 
comparing PCV7, PCV10, and PCV13 alternatives. 
The time span for all interventions was three years, 
and an annual discount rate of 3% was used [36].  
The PNIS for 2011 included three doses (2+1) of 
PCV, two doses in the first year and a third dose at 12 
months or more in the second year [39]. Although 
other PCV studies used three doses plus a booster 
(3+1) in children between two months and two years 
of age, the Pan American Health Organization 
(PAHO) and the World Health Organization (WHO) 
expert panels recommend three doses for any PCV as 
the minimum number to be considered in a vaccination 
schedule [40]. For this study, three doses (2+1) were 
considered to be the complete schedule of vaccination 
against S. pneumoniae. 
 
Health outcomes and measurement of effectiveness 
Vaccine effectiveness for all alternatives was 
defined as that which prevented or avoided 
hospitalizations due to PP. The main goal of the 
Peruvian government is the reduction of child 
mortality and malnutrition; PP is strongly associated 
with these conditions. Hence, the MINSA’s request 
was focused on PP as the main outcome. 
 
Systematic search of literature 
First, an investigation was undertaken to determine 
whether PCV7, PCV10, and PCV13 intervention 
among children under five years of age reduces the 
incidence of pneumonia, meningitis, or acute otitis 
media. Studies were selected from a search of papers 
in the following databases: Cochrane Library, 
PubMed/MEDLINE, EMBASE, Latin American 
Literature on Health Sciences (LILACS), and 
Scientific Electronic Library Online (SciELO). Studies 
from January 2005 to December 2010 were selected. 
References identified were limited to randomized 
controlled trials (RCTs), observational studies, and 
systematic reviews with or without meta-analysis 
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(MA), conducted in children under five years of age. 
Review papers, editorials, and conference abstracts 
were excluded. 
 
Three searches were used.  
Search 1 included ("7-valent pneumococcal* 
vaccine") AND ("pneumonia" OR “meningitis” OR 
“acute otitis media”); 
Search 2 included ("10-valent pneumococcal* 
vaccine") AND ("pneumonia" OR “meningitis” OR 
“acute otitis media”); and 
Search 3 included ("13-valent pneumococcal* 
vaccine") AND ("pneumonia" OR “meningitis” OR 
“acute otitis media”). 
 
Second, an exhaustive review of references in the 
primary identified sources was done to complement 
the systematic search. National and international 
experts were asked to provide additional 
bibliographical searches and knowledge about 
additional available studies not identified by 
investigators. Given that no studies were found for 
meningitis and acute otitis media, the CEA was done 
for pneumonia only, specifically for PP, as this 
allowed the evaluation of pneumococcal serotype 
distribution in the country. 
 
Estimation of resources and costs 
Costs were calculated based on real costs from the 
perspective of the MINSA according to the PNIS. 
Direct medical costs for inpatient care, including 
average diagnosis and treatment costs of hospitalized 
patients with pneumococcal pneumonia, were obtained 
from three major general hospitals in Lima: Hospital 
Nacional Arzobispo Loayza, Hospital San Juan de 
Lurigancho, and Instituto Nacional de Salud del Niño. 
For cost estimations of PCV10 and PCV13, 
manufacturers of PCVs were contacted. Also, 
approximately 15% of the direct costs were estimated 
to be indirect costs, according to Ministry of Health 
calculations. All currency values were expressed in 
USD for 2011, which was the year the model was 
developed (1 USD = 2.8 Peruvian nuevos soles).  
 
Pharmacoeconomic model 
A decision tree analysis-based model was used. 
This represented the probable clinical evolution in a 
temporal horizon of three years, applying three 
alternative preventing interventions with PCV7, 
PCV10, and PCV13. Each branch of the model 
decision tree represented one of these preventing 
options, and the final results of each of the branches 
combine the serotype isolation in the corresponding 
vaccine with associated cost and final clinical 
effectiveness (avoided hospitalizations) (Figure 1). 
For outcome assessment, the relation of cost-
effectiveness for each option was calculated, with the 
most efficient option being the one with the lowest 
value. Also, the incremental cost-effectiveness ratio 
(ICER) of all the alternatives was estimated; this 
evaluated the necessary cost to avoid an extra 
hospitalization due to PP. 
Figure 1. Decision tree analysis of three PCV varieties 
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The decision tree model is represented based on 
the CEA. Branches of the tree show the possible 
evolution of the interventions, assuming that all can 
possibly reduce the incidence of pneumonia. At 
branches, the probabilities of serotype isolation 
(included in the corresponding vaccine) are 
represented according the observational available 
information based on epidemiological data of 
hospitalized children (Figure 1). 
Probabilistic sensitivity analyses were performed 
to assess the effect of uncertainty around the model 
results. First, cost-effectiveness acceptability curves 
were created. Second, considering the best fitted 
distribution explaining the performance of each 
variable –normal distribution in the most variables (for 
building the range of incidence rate for serotypes 
include in each vaccine, we using in that way, the 
worse a best scenario) and log-normal distribution in 
the case of costs– a Monte Carlo simulation was 
conducted (1,000 simulations were run, each selecting 
an input within the distribution). This process allowed 
for the estimation of a range of possible model 
outcomes. Finally, tornado analysis was done to 
evaluate the variables with major influence in final 
cost-effectiveness results [36,41,42].  




Study parameters and findings of the systematic 
search 
No systematic reviews, MAs, or RCTs comparing 
clinical efficacy and effectiveness of PCV10 and 
PCV13 were found. Two observational studies by 
Hortal et al. [43] and Cedrés et al. [44], considered to 
be relevant sources for the analysis, were selected. 
These studies were based on epidemiological 
surveillance information from Uruguay, a middle-
income Latin American country with a population of 
approximately three million. These studies assessed 
the pneumococcal serotype incidence in a pediatric 
population of children under five years of age in PCV7 
pre-vaccination and post-vaccination periods. This 
information was used because the baseline serotype 
distribution (pre-vaccination period) was similar to 
that of the Peruvian population [45]. Effectiveness 
data for PCV10 and PCV13 were extrapolated from 




According to Hortal et al., 314 cases of pneumonia 
were recorded in a population of children under five 
years of age during the PCV7 pre-vaccination period 
(2000–2004). Serotype distribution was 52% for 
PCV7 vaccine-included serotypes (4, 6B, 9V, 14, 18C, 
19F, 23F), 34% for additional serotypes included in 
the PCV10 (1, 5, 7F), 12% for additional serotypes 
included in the PCV13 (3, 6A, 19A); and 2% for other 
serotypes not included in these PCVs in Uruguay [43].  
Cedrés et al. [44], after the introduction of PCV7 
in Uruguay, reported 61 cases of PP in a population of 
children under five years of age vaccinated with PCV7 
in the post-vaccination period (2008–2009). Serotype 
distribution was 38% for PCV7 vaccine-included 
serotypes; 39% for PCV10 vaccine-included 
additional serotypes; 15% for PCV13 vaccine-
included additional serotypes; and 8% for other 
serotypes not included in these PCVs [44].  
The relative risk (RR) of PCV7-serotypes 
pneumonia between post- and pre-vaccination periods 
was 0.73; based on these point estimates, a RR 
reduction of 27% was achieved with PCV7. This has 
been defined as a direct effect (DE) of PCV7 vaccine 
in this cohort. 
Considering the lack of prospective studies 
assessing the clinical efficacy of PCV10 and PCV13 
until 2009, the pneumonia risk reduction of these 
vaccines was estimated based on the assumption that 
both would have the same DE as PCV7. Of note, 
PCV10 and PCV13 included the same serotypes 
available in PCV7 plus an additional DE that would 
correspond to a factor defined in previous studies 
[24,46-48]. For PCV10, this factor would be estimated 
as (pre-vaccination PCV10 serotypes incidence [not 
included in PCV7])/(pre-vaccination PCV7 serotypes 
incidence). Similarly, the additional DE for PCV13 
would be estimated as (pre-vaccination PCV13 
serotypes incidence [not included in PCV10])/(pre-
vaccination PCV7 serotypes incidence). The total DE 
of PCV10 would be DE(PCV10) = DE(PCV7) x (pre-
vaccination PCV10 serotypes incidence/pre-
vaccination PCV7 serotypes incidence), and the total 
DE for PCV13 would be DE(PCV13) = DE(PCV7) x 
(pre-vaccination PCV13 serotypes incidence/pre-
vaccination PCV7 serotypes incidence). 
According to this, given the epidemiological 
surveillance in Uruguay, the DE for PCV10 would be 
0.73 x (0.34/0.52), and for PCV13 would be 0.73 × 
(0.12/0.52). The final DE would be 0.48 and 0.17 for 
PCV10 and PCV13, respectively. These values 
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correspond to a relative risk reduction of 52% and 
83%, respectively. 
According to the general direction of 
epidemiology of MINSA [49], the annual incidence of 
pneumonia is around 130 cases/100,000 children 
under five years of age. Of these cases, 40% are due to 
S. pneumoniae, which represents approximately 52 
cases of PP per 100,000 children under five years of 
age per year [49]. Based on the reports of the Peruvian 
National Institute of Health until year 2009 (pre-
vaccination introduction year), 62%, 71%, and 82% of 
isolates would correspond to serotypes included in the 
PCV7, PCV10, and PCV13 vaccines [45], 
respectively. Thus, incidence rates would be 32 
cases/100,000 for PCV7 serotypes, 37 cases/100,000 
for PCV10 serotypes, 43 cases/100,000 for PCV13 
serotypes; 9 cases/100,000 would approximately 
correspond to serotypes not included in current PCVs.  
In terms of CEA, the post-vaccination incidence 
could be estimated to be 38%, 41%, and 17% for the 
development of pneumonia with serotypes included in 
PCV7, PCV10, and PCV13, respectively. Considering 
the DE of these three vaccines and a coverage of 
100%, the annual incidence of PP due to serotypes of 
PCV7 in children under five years of age would 
decrease from 32 (pre-vaccination period) to 12 
cases/100,000 (post-vaccination period; i.e., 52 × 0.62 
× 0.38). Thus, overall pneumonia cases would be 
reduced from 52/100,000 to 32/100,000 per year. 
Similarly, the annual incidence of PP due to serotypes 
of PCV10 would be reduced from 37 to 15/100,000 
(52 × 0.71 × 0.41); i.e., overall pneumonia cases 
would be reduced from 52/100,000 to 30/100,000 per 
year. Finally, pneumonia associated with PCV13 
serotypes would decrease from 43 to 7/100,000 (52 × 
0.82 × 0.17); i.e., overall pneumonia cases reduced 
from 52/100,000 to 16/100,000 per year. Although 
these are only point estimates, a similar distribution of 
serotypes among hospitalized and non-hospitalized 
patients is assumed. 
According to the decision tree, the probability of 
serotype isolation would be 38%, 41%, and 17% for 
PCV7, PCV10, and PCV13, respectively.  
 
Costs 
In Table 1, the total cost for a hypothetical cohort 
of 100 vaccinated children with each PCV in 
evaluation is shown. PCV7 has the highest cost, and 
the PCV13 cost is higher than that of PCV10. Those 
estimations include fixed and variable costs (direct 
Table 1. Direct and indirect costs of vaccination with PCV7, PCV10, PCV13 
 
Costs in USD 
PCV7 PCV10 PCV13 
Fixed costs 1.17 1.17 1.17 
Human resources 0.88 0.88 0.88 
Depreciation 0.29 0.29 0.29 
Variable costs 21.52 16.37 17.86 
Materials and devices 0.72 0.72 0.72 
Vaccines 20.00 14.85 16.34 
Services 0.80 0.80 0.80 
Direct costs (fixed + variable costs) 22.69 17.54 19.03 
Indirect costs 3.40 2.63 2.85 
Total costs x 1 dose 26.09 20.17 21.88 
N° of doses 3 3 3 
Total costs x 3 doses 78.28 60.51 65.65 
Total costs x 100 vaccinated children 7,828 6,051 6,565 
 
Table 2. Average costs of hospitalization due to pneumonia in children in Lima, Peru 
Parameter description Quantity Unit price (USD) Total costs (USD) 






Complete blood counts (CBC) 
  
2.33 
Hemoculture (1 sample/bottle) 
  
5.03 
1 day of hospitalization in a general ward (/child) 7 6.11 42.76 
Vial of ceftriaxone 14 0.61 8.50 
Syringe d/c of 1 cc c/a of 25’ 5/8” 14 0.06 0.90 
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costs) plus indirect costs. Table 2 summarizes the 
estimated costs of treatment for each hospitalization 
case at the MINSA institutions. In Table 3, the 
potential cost for a hypothetical cohort of 100 children 
vaccinated with PCV7 and hospitalized due to 
pneumonia is estimated to be USD 13,761. Similarly, 
for a cohort of 100 PCV10-vaccinated children 
hospitalized due to pneumonia, a potential cost of 
USD 11,985 was estimated. Finally, a similar cohort 
of 100 PCV13-vaccinated hospitalized children with 
pneumonia would have an estimated potential cost of 
USD 12,499.  
 
Cost-effectiveness ratio (CE ratio) and incremental 
cost-effectiveness ratio 
An estimation of CE ratios is presented in Table 3. 
This corresponds to USD 718 for PCV7, USD 333 for 
PCV10, and USD 162 for PCV13 per avoided 
hospitalization. These results indicate that 
interventions with PCV10 and PCV13 are more cost 
effective than those with PCV7; however, intervention 
with PCV10 would be less cost effective than with 
PCV13 when baseline strategy PCV7 is eliminated. 
Figure 2 shows the point estimates of CE ratio for the 
three alternatives, considering at the y-axis the costs 
per 100 vaccinated children and at the x-axis avoided 
hospitalizations. For example, the use of PVC7 in 100 
children would cost USD 13,800 to avoid 19 
hospitalizations. The summary for the analysis of 
ICER is shown in Table 3. Cost per avoided 
hospitalization would be lowest with PCV13 (USD 
162) than PCV10 (USD 333) and PCV7 (USD 718). 
PCV7 is less cost effective than PCV10 and PCV13. 
However, PCV13 would be more cost effective than 
PCV10 when PCV7 is eliminated, with an estimated 
ICER of 13.   
Sensitivity analysis 
In the worst-case scenario for PCV7, no 
pneumonia cases would be avoided, and in the best-
case scenario, 48 cases would be avoided. The worst-
case scenario for PCV10 and PCV13 would 
correspond to the worst-case scenario for PCV7 (0 
avoided pneumonia cases), and the DE would be 33 
avoided pneumonia cases for PCV10 and 76 for 
PCV13. The best-case scenario for PCV10 and PCV13 
would begin with the best-case scenario for PCV7 (48 
avoided cases), plus the DE (66 avoided cases for 
PCV10, and 88 for PCV13). For cases in which other 
serotypes were isolated (not included in any of the 
assessed vaccines), it is assumed that no cases would 
be avoided (0 avoided pneumonia cases). 
Acceptability curves for the interventions are shown in 
Figure 3. The probability of cost effectiveness for 
PCV13 is around 40% when willingness to pay is 
USD 0; beginning with a willingness to pay USD 30, 
PCV13 has a higher probability of cost effectiveness 
than does PCV10 (> 50%). However, PCV10 and 
PVC7 were never more cost effective than PCV13 for 
any level or amount of willingness to pay. 
The Monte Carlo probabilistic simulation is 
presented in Figure 4, showing the scatter plot of 
PCV13 located at the right-hand side of PCV7 and 
PCV10, with practically no overlap between PCV13 
and PCV10 and little overlap between PCV7 and 
PCV10. Differences between them are clear, showing 
that PCV13 and PCV10 are more cost effective than 
PCV7. Additionally, PCV13 is more cost effective 
than PCV10, although this intervention has a slightly 
higher cost. The tornado diagram in Figure 5 shows 
the most influential variable on the final results of the 
model.  







(USD per avoided hospitalization) 
ICER 
 
PCV7 19.16 13,761 718 Dominated 
 
PCV10 36.00 11,985 333 -105 PCV10 vs PCV7 
PCV13 76.94 12,499 162 13 PCV13 vs PCV10 
 
Table 4. Value parameters of the economic model 
Variable Mean Value (range) Distribution 
Hospitalization cost (USD) 5,951 (5,000 – 7,000) LogNormal 
PCV10 cost (USD) 2,017 (1,800 – 2,500) LogNormal 
PCV13 cost (USD) 2,188 (1,800 – 2,500) LogNormal 
PCV7 cost (USD) 2,609 (2,000 – 3,000) LogNormal 
Avoided hospitalizations with PCV10 60 (40 – 90) Normal 
Avoided hospitalizations with PCV13 93 (40 – 100) Normal 
Avoided hospitalizations with PCV7 31 (20 – 40) Normal 
 
Mezones-Holguín et al. – Cost effectiveness of PCVs in Peruvian children    J Infect Dev Ctries 2014; 8(12):1552-1562. 
1558 
  Figure 2. CE relation between the three vaccine varieties (per 
100 children < 5 years of age vaccinated) (AH = avoided 
hospitalizations) 
Figure 3. Acceptability curve for three vaccine varieties 
Figure 4. Probabilistic sensitivity test for the three vaccine 
varieties using the Monte Carlo simulation method 
Figure 5. Tornado diagram 
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According to this, effectiveness variation for 
pneumonia in PCV13-vaccinated children and cost per 
dose of PCV13 would be the variables that have a 
greater impact on the net monetary benefit.  
Finally, the values, ranges, and probability 
distributions for all parameters used to represent 
uncertainty are shown in Table 4. 
 
Discussion 
Our findings show that PCV13 would be more cost 
effective than PCV10 in the prevention of PP in 
children under five years of age when PCV7 is 
eliminated. Moreover, if PCV7 were maintained in the 
analysis, PCV7 would be less effective than PVC10 
and PCV13. These results are due to PVC13’s higher 
effectiveness in preventing more hospitalizations due 
to pneumococcal pneumonia than PCV10 despite the 
lower cost of PCV10.  
Beneficial effects of PCVs on at-risk populations 
have been described. The efficacy of PCV7 was 
demonstrated in clinical trials prior to 
commercialization [12,50], and it was subsequently 
introduced into immunization schedules in several 
countries, including Peru [51]. Moreover, prospective 
results of efficiency of PCV10 and PC13 are still 
necessary, particularly for regions such as Latin 
America and especially Peru. This country has a 
comprehensive immunization program, in which 
MINSA provides vaccines to the whole population 
through the social security system and, in some cases, 
within the private sector [39,51]. There have been 
studies assessing cost effectiveness of PCV7 
[23,27,28,52], but few studies assessing PCV10 and 
PCV13 [29,32,35] have been conducted in this part of 
the world.  
This study is a first approach at measuring the 
efficiency –since EE involves cost and effectiveness 
related whichever intervention in health [36,37,53]– of 
available vaccination alternatives to support decision 
making in Peru. This study is of utmost importance, 
especially to countries such as Peru with estimated 
IPD rates in children under 24 months of age in Lima 
of 18.4 cases/100,000 [4] and where pneumonia is the 
major problem related to child mortality [54]. Also, 
EEs are an important tool for making decisions in 
public health interventions because of their budgetary 
impact; furthermore, because vaccination programs are 
provided by the public sector, vaccination programs 
are among the most frequently studied public health 
interventions [29,55,56]. This mainly occurs in 
countries where the financial support for those 
programs is funded by the government, especially 
because economic evaluations results are context 
dependent [37,57]. Given the Peruvian MINSA 
provides vaccines for all infants and toddlers through 
the PNIS [39], deciding on an alternative with the 
highest cost effectiveness and largest reductions in 
children mortality is mandatory. Thus, in the Peruvian 
context, the PCV13 vaccine is the best alternative. 
However, it is important to take into account other 
conditions or perspectives that could guide the 
complexity of decision making [37,58]. 
Our study has some limitations. First, the 
pharmacoeconomic analysis was not based on direct 
data of the epidemiological surveillance of Peru 
because there are no local observational reports for a 
PCV7 post-vaccination period or any systematic 
review or RCT which compares directly the efficacy 
of both vaccines (PV10 and PCV13) to estimate 
efficacy. We used information from the 
epidemiological surveillance in Uruguay, a country 
that had a similar pneumococcal serotypes distribution 
to Peru in the PCV7 pre-vaccination period [43,44]; 
thus, we extrapolated the direct effect by standardized 
international methods [24,46-48]. However, 
observational designs are of high relevance and utmost 
importance in CEA [59,60]. The second limitation was 
our use of only pneumonia as the outcome, to the 
exclusion of pneumococcal meningitis, sepsis, and 
otitis media; this was because available evidence is 
still limited and the record systems for these diseases 
in Peru are scarce. Third, because we did not 
categorize the clinical form of pneumonia (empyema, 
with or without bacteremia), the estimations are 
limited to uncomplicated PP; we assumed a similar 
distribution of the complications and development of 
diseases for all types of serotypes, thus it does not 
produce any variation in the model. Finally, indirect 
effect by herd immunity of PCVs was not measured. 
The estimation of this effect can have a significant 
clinical impact on a non-vaccinated pediatric 
population, may decrease the severity given the 
reduction of invasive serotypes circulation, and 
eventually also may prevent disease in a non-
vaccinated population [61-64]. However, including 
this estimation could increase the uncertainty of the 
model, especially when we do not have exact 
estimations. Also, our model is static, so it may not 
reflect the real world by including the dynamic 
transmission of pneumococcal pneumonia in the 
community, where the indirect effect has important 
implications [65].  
An inherent feature of pharmacoeconomic designs 
is the fact they are regularly assessed by different 
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sensitivity tests, which examine the robustness of 
results against uncertainty of each variable [66]. Thus, 
the robustness of our results was supported with 
probabilistic sensitivity tests, in which it was observed 
that PCV13 is better than the other two alternatives in 
terms of cost effectiveness in the Peruvian context; 
this is one of strengths of our study.  
According to our results, interventions with 
PCV10 and PCV13 are more cost effective in the 
reduction of hospitalizations due to pneumonia than 
interventions with PCV7, although PCV7 is less cost 
effective the other two interventions. PCV13 is more 
cost effective than PCV10. It is necessary to assess the 
impact of PCVs after their introduction because they 
are an important investment for the government and 
because assessment allows for a better use of resources 
and enhances public health policies [67]. 
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